Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.63 |
| ▸ | HTR7 | P34969 | 9/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD5 | P21918 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715989 | 0.90 | DRD2 (0.59) | HTR1AHTR7HRH4DRD2DRD3 | |
| SCHEMBL6711688 | 0.89 | HRH4 (0.52) | HTR1AHTR7HRH4DRD2DRD3 | |
| SCHEMBL6715613 | 0.88 | HTR1A (0.49) | HTR1AHTR7HRH4DRD2DRD5 | |
| SCHEMBL7084667 | 0.88 | HRH4 (0.51) | HTR1AHTR7HRH4DRD2DRD3 | |
| SCHEMBL7087322 | 0.88 | HRH4 (0.51) | HTR1AHTR7HRH4DRD2DRD3 | |
| SCHEMBL6977709 | 0.84 | GRIN1 (0.66) | HTR1AHTR7DRD2DRD3DRD4 | |
| SCHEMBL6973851 | 0.84 | DRD2 (0.59) | HTR1AHRH4DRD2DRD3DRD4 | |
| SCHEMBL7085853 | 0.83 | HRH4 (0.55) | HTR1AHTR7HRH4DRD3HTR1D | |
| SCHEMBL6978625 | 0.83 | GRIN1 (0.58) | HTR1AHTR7HRH4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL6711485 | 0.83 | DRD2 (0.57) | HTR1AHRH4DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138203-A1 | Bicyclic lactams and sulfonamides with 5-ht1a -affinity and use thereof for preventing and treating cerebral ischaemia | STEINER GERD | 2004-07-15 | — | — | US | disclosed |
| EP-1296954-A1 | BICYCLIC LACTAMS AND SULFONAMIDES WITH 5-HT1A-AFFINITY AND USE THEREOF FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | Abbott GmbH & Co. KG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002002529-A1 | BICYCLIC LACTAMS AND SULFONAMIDES WITH 5-HT1A-AFFINITY AND USE THEREOF FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | ABBOTT GMBH & CO. KG (DE) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138203-A1 | Bicyclic lactams and sulfonamides with 5-ht1a -affinity and use thereof for preventing and treating cerebral ischaemia | HTR1A, HTR5A, HTR2C | HTR1A 1/4885HTR7 13/4885HRH4 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.